The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There is only one clown here. And thats the smooth brain who sits on a forum for a company he hates all days spewing bullsht
People back flipping because its blue and nearly 2p
absolute clowns!!!
Over £2 million plus raised this month. No placing required before derampers start deramping on placing and funds. See previous Rns.
Here we go ..!!
Do people that bought under 10p realise the massive vast number of bag holders with this share????????????
Placing also done this month. No need to raise funds. DYOR.
Easy 20p next couple of months. imho..dyor
Last year June was 20p. How times have changed. Hopefully this Rns will try and get it back up now
RNS printed on the LSE Board. Excellent news. Should see peeps loading onto this share now.
Someone is likely to acquire this company
NICE guidance is not optional - there is a massive focus on health inequalities and if someone in the 30% has an adverse event due to either under or over metabolism of clopidogrel then there will be a legal liability. So Trusts and providers will have to be using this test. Would expect very rapid uptake across the NHS
This news will open up sales in the European market in early 2025.
In context, CE-IVD certification is a proof of compliance with current regulations and standards. It is required for commercialization in vitro diagnostics (IVD) devices in Europe.
And......i loved the nod to NICE being on track for the 10th July:
"The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patients (https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents). The draft guidance is expected to be finalised on 10 July 2024."
Great News!
GLA.
Stephen11
Exactly & with over 77 million people globally having ischaemic strokes each year there is a huge gap in the market for GDR to exploit.
* The key point is GDR's CYP2C19 ID stroke Kit targets the most common type of stroke
* The UK Stroke Association estimate that there are 100,000 strokes each year in our country
* The EU market for CYP2C19 could be worth £93.5m each year to GDR according to recent guidance
* The UK market for CYP2C19 could be worth £8.5 m each year in revenues to GDR
These numbers are not to be sniffed at....
Good luck, Brighty
Big Pharma jV will follow now
The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patients
That reads decent tbf
Where’s the money coming from to keep going ?
Massive achievement after a long wait and way overdone stock.
Ey CYP2C19-ID test performance milestone achieved
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that a key milestone has been met in The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") programme for its CYP2C19-ID kit. The programme has now passed the patient numbers required for a subsequent submission for an in vitro diagnostics CE certification ("CE-IVD"), which is still anticipated in early 2025.
The Genedrive® CYP2C19-ID point of care genetic test is UK Conformity Assessed ("UKCA") certified, uses a single, non-invasive cheek swab sample, and rapidly identifies several important genetic variants of the CYP2C19 gene (Loss Of Function ("LoF")), which are instrumental in an individual's response to the drug clopidogrel which can be prescribed in Ischemic Stroke ("IS") and Transient Ischaemic Attack ("TIA"). The test automatically interprets the CYP2C19 DNA variant information for the clinician and allows for prompt administration of an alternative treatment plan for the circa 30% of individuals that are less likely to respond favourably to clopidogrel.
DEVOTE is an all-comer study in which CYP2C19 DNA variants in patients presenting in the acute emergency care setting are tested with the Genedrive® CYP2C19-ID test and results compared with those obtained by reference laboratory platform testing, with testing on a third laboratory platform in instances where there is disagreement in test results. In the tests run to date the Genedrive® CYP2C19-ID test has out-performed the reference laboratory-based test with respect to coverage of LoF variants and accuracy (correct identification of variant).
The DEVOTE programme, through its lead partner the University of Manchester ("UoM"), has supported the Company's requirement for assessing performance in acute care patients and provided valuable supporting infrastructure to assess the real-world clinical performance of time-critical clinical tests in NHS settings. The study addresses clinical requirements of the In Vitro Diagnostic Medical Devices Regulation ("IVDR") for CE-IVD submission and subsequent commercialisation in those countries recognising CE-IVD, in addition to current UKCA certification allowing UK commercialisation.
Approximately 30% of patients in the cohort harboured CYP2C19 LoF variants as expected. The Genedrive® CYP2C19 test outperformed the laboratory test with respect to accuracy of identification of LoF alleles, and broader inclusion of LoF alleles. Genedrive® CYP2C19-ID test results are available in ~70 minutes.
The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patients (https://www.nice.org.uk/guidance/indevelopment/gid-d
Nothing stopping this quickly of returning to 10p
Key CYP2C19-ID test performance milestone achieved
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that a key milestone has been met in The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") programme for its CYP2C19-ID kit. The programme has now passed the patient numbers required for a subsequent submission for an in vitro diagnostics CE certification ("CE-IVD"), which is still anticipated in early 2025.
GLA.
Stephen11.
Speaking if hitting a milestone, milestone rns
Positive RNS
Should see a little pump to .20